Kenneth G. Trieu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenneth G. Trieu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Juliana Barrios
The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
2 shared publications- Kruti Rajan Patel
The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
2 shared publications Wei Wang
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
2 shared publications- Xingbin Ai
Division of Newborn Medicine, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publications Yan Bai
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
2 shared publicationsAlan Fine
The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, USA; The West Roxbury Veteran's Hospital, West Roxbury, MA, USA
1 shared publication
Latest Publications
- Open Access
- 9 November 2026
- Published by Springer Nature in EMBO Molecular Medicine
N-Myc promotes a proliferative progenitor-like cell state to drive basal cell carcinoma progression
Driver mutations that activate upstream Hedgehog (Hh) signaling are well-known to initiate basal cell carcinoma (BCC); however, the role of recurrent secondary mutations is less well understood. Here, we performed spatial transcriptomics to show that nascent murine BCC-like tumors are initially comprised of two subpopulations that differ in expression of Hh, stem cell, and differentiation markers. Using a newly developed cell culture formulation that we termed “RRi conditions”, we established several mouse BCC cell lines, benchmarked them against existing ASZ BCC cells, and identified novel genes associated with Hh activation ( Wnt7b , Tgfb3 , Cxcl14 ). We further show that inducible N-MYC expression promotes an NICD low ;K10 low ;Ki67+ undifferentiated cell state, similar to that of transit-amplifying hair follicle progenitors, and that genetically ablating N-Myc blunts tumor formation in mice. Finally, we report that an immunomodulatory drug, imiquimod, regresses nascent lesions and destabilizes N-MYC protein, an effect that depends upon GSK3 and proteasome activity. Altogether, our findings demonstrate that BCCs upregulate N-MYC to maintain a proliferative progenitor-like cell state, and support the use of imiquimod to restrict tumor progression.
- 9 November 2026
- Published by Springer Nature in EMBO Molecular Medicine
Open AccessN-Myc promotes a proliferative progenitor-like cell state to drive basal cell carcinoma progression
Driver mutations that activate upstream Hedgehog (Hh) signaling are well-known to initiate basal cell carcinoma (BCC); however, the role of recurrent secondary mutations is less well understood. Here, we performed spatial transcriptomics to show that nascent murine BCC-like tumors are initially comprised of two subpopulations that differ in expression of Hh, stem cell, and differentiation markers. Using a newly developed cell culture formulation that we termed “RRi conditions”, we established several mouse BCC cell lines, benchmarked them against existing ASZ BCC cells, and identified novel genes associated with Hh activation ( Wnt7b , Tgfb3 , Cxcl14 ). We further show that inducible N-MYC expression promotes an NICD low ;K10 low ;Ki67+ undifferentiated cell state, similar to that of transit-amplifying hair follicle progenitors, and that genetically ablating N-Myc blunts tumor formation in mice. Finally, we report that an immunomodulatory drug, imiquimod, regresses nascent lesions and destabilizes N-MYC protein, an effect that depends upon GSK3 and proteasome activity. Altogether, our findings demonstrate that BCCs upregulate N-MYC to maintain a proliferative progenitor-like cell state, and support the use of imiquimod to restrict tumor progression.
- Open Access
- 16 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 818
Foxo1 Promotes Th9 Cell Differentiation and Airway Allergy
T helper 9 (Th9) cells are effector CD4+ T cells that are characterized by the production of interleukin-9 (IL-9) and have been associated with allergic responses. Here, we found that the expression of the transcription factor forkhead box O1 (Foxo1) was induced in Th9 and Foxo1 plays a crucial role in the differentiation of Th9 cells. Pharmacological inhibition of Foxo1 or genetic disruption of Foxo1 in CD4+ T cells caused a reduction in IL-9 expression while upregulating IL-17A and IFNγ production. Furthermore, chromatin immunoprecipitation (ChIP) followed by luciferase assays revealed direct binding of Foxo1 to both the Il9 and Irf4 promoters and induces their transactivation. Lastly, adoptive transfer of Th9 cells into lungs induced asthma-like symptoms that were ameliorated by Foxo1 inhibitor, AS1842856. Together, our findings demonstrate a novel regulator of Th9 cells with a direct implication in allergic inflammation.
- 16 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 818
Open AccessFoxo1 Promotes Th9 Cell Differentiation and Airway Allergy
T helper 9 (Th9) cells are effector CD4+ T cells that are characterized by the production of interleukin-9 (IL-9) and have been associated with allergic responses. Here, we found that the expression of the transcription factor forkhead box O1 (Foxo1) was induced in Th9 and Foxo1 plays a crucial role in the differentiation of Th9 cells. Pharmacological inhibition of Foxo1 or genetic disruption of Foxo1 in CD4+ T cells caused a reduction in IL-9 expression while upregulating IL-17A and IFNγ production. Furthermore, chromatin immunoprecipitation (ChIP) followed by luciferase assays revealed direct binding of Foxo1 to both the Il9 and Irf4 promoters and induces their transactivation. Lastly, adoptive transfer of Th9 cells into lungs induced asthma-like symptoms that were ameliorated by Foxo1 inhibitor, AS1842856. Together, our findings demonstrate a novel regulator of Th9 cells with a direct implication in allergic inflammation.
- Open Access
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (10) , 4335-4346
Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma
Asthma often progresses into adulthood from early‐life episodes of adverse environmental exposures. However, how the injury to developing lungs contributes to the pathophysiology of persistent asthma remains poorly understood. In this study, we identified an age‐related mechanism along the cholinergic nerve–airway smooth muscle (ASM) axis that underlies prolonged airway hyperreactivity (AHR) in mice. We showed that ASM continued to mature until ~3 wk after birth. Coinciding with postnatal ASM maturation, there was a critical time window for the development of ASM hypercontractility after cholinergic stimulation. We found that allergen exposure in neonatal mice, but not in adult mice, elevated the level and activity of cholinergic nerves (termed neuroplasticity). We demonstrated that cholinergic neuroplasticity is necessary for the induction of persistent AHR after neonatal exposure during rescue assays in mice deficient in neuroplasticity. In addition, early intervention with cholinergic receptor muscarinic (ChRM)‐3 blocker reversed the progression of AHR in the neonatal exposure model, whereas β2‐adrenoceptor agonists had no such effect. Together, our findings demonstrate a functional relationship between cholinergic neuroplasticity and ASM contractile phenotypes that operates uniquely in early life to induce persistent AHR after allergen exposure. Targeting ChRM3 may have disease‐modifying benefits in childhood asthma.—Patel, K. R., Bai, Y., Trieu, K. G., Barrios, J., Ai, X. Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma. FASEB J. 31, 4335–4346 (2017). www.fasebj.org
- 19 September 2017
- Published by Wiley in The FASEB Journal
- Vol. 31 (10) , 4335-4346
Open AccessTargeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma
Asthma often progresses into adulthood from early‐life episodes of adverse environmental exposures. However, how the injury to developing lungs contributes to the pathophysiology of persistent asthma remains poorly understood. In this study, we identified an age‐related mechanism along the cholinergic nerve–airway smooth muscle (ASM) axis that underlies prolonged airway hyperreactivity (AHR) in mice. We showed that ASM continued to mature until ~3 wk after birth. Coinciding with postnatal ASM maturation, there was a critical time window for the development of ASM hypercontractility after cholinergic stimulation. We found that allergen exposure in neonatal mice, but not in adult mice, elevated the level and activity of cholinergic nerves (termed neuroplasticity). We demonstrated that cholinergic neuroplasticity is necessary for the induction of persistent AHR after neonatal exposure during rescue assays in mice deficient in neuroplasticity. In addition, early intervention with cholinergic receptor muscarinic (ChRM)‐3 blocker reversed the progression of AHR in the neonatal exposure model, whereas β2‐adrenoceptor agonists had no such effect. Together, our findings demonstrate a functional relationship between cholinergic neuroplasticity and ASM contractile phenotypes that operates uniquely in early life to induce persistent AHR after allergen exposure. Targeting ChRM3 may have disease‐modifying benefits in childhood asthma.—Patel, K. R., Bai, Y., Trieu, K. G., Barrios, J., Ai, X. Targeting acetylcholine receptor M3 prevents the progression of airway hyperreactivity in a mouse model of childhood asthma. FASEB J. 31, 4335–4346 (2017). www.fasebj.org
- 6 September 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (38) , 10583-10588
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua
Significance: The transcriptional repressor protein Capicua (Cic) is a conserved regulator of organ growth and tissue patterning, and mutations in the CIC gene in humans result in the brain cancer oligodendroglioma. Cic activity is controlled by the receptor tyrosine kinase (RTK) signaling pathway. Here, we identify the kinase Minibrain (Mnb) and its adaptor Wings apart (Wap) as Cic regulators. Mnb and Wap bind to and phosphorylate the Cic protein, and inhibit the ability of Cic to repress gene expression. Mnb-dependent down-regulation of Cic is necessary for the proper growth of multiple organs and correct the patterning of tissues. Our results uncover a previously unknown mechanism of Cic regulation that acts in parallel to other growth-controlling pathways.
- 6 September 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (38) , 10583-10588
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua
Significance: The transcriptional repressor protein Capicua (Cic) is a conserved regulator of organ growth and tissue patterning, and mutations in the CIC gene in humans result in the brain cancer oligodendroglioma. Cic activity is controlled by the receptor tyrosine kinase (RTK) signaling pathway. Here, we identify the kinase Minibrain (Mnb) and its adaptor Wings apart (Wap) as Cic regulators. Mnb and Wap bind to and phosphorylate the Cic protein, and inhibit the ability of Cic to repress gene expression. Mnb-dependent down-regulation of Cic is necessary for the proper growth of multiple organs and correct the patterning of tissues. Our results uncover a previously unknown mechanism of Cic regulation that acts in parallel to other growth-controlling pathways.